Individualized screening interval for prostate cancer based on prostate-specific antigen level: results of a prospective, randomized, population-based study.
BACKGROUND: The aim of the present study was to evaluate the future cumulative risk of prostate cancer in relation to levels of prostate-specific antigen (PSA) in blood and to determine whether this information could be used to individualize the PSA testing interval. METHODS: The study included 5855...
| Main Authors: | , , , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
2005
|
| _version_ | 1826271110096748544 |
|---|---|
| author | Aus, G Damber, J Khatami, A Lilja, H Stranne, J Hugosson, J |
| author_facet | Aus, G Damber, J Khatami, A Lilja, H Stranne, J Hugosson, J |
| author_sort | Aus, G |
| collection | OXFORD |
| description | BACKGROUND: The aim of the present study was to evaluate the future cumulative risk of prostate cancer in relation to levels of prostate-specific antigen (PSA) in blood and to determine whether this information could be used to individualize the PSA testing interval. METHODS: The study included 5855 of 9972 men (aged 50-66 years) who accepted an invitation to participate in a prospective, randomized study of early detection for prostate cancer. We used a protocol based on biennial PSA measurements starting from 1995 and 1996. Men with serum PSA levels of 3.0 ng/mL or more were offered prostate biopsies. RESULTS: Among the 5855 men, 539 cases of prostate cancer (9.2%) were detected after a median follow-up of 7.6 years (up to July 1, 2003). Cancer detection rates during the follow-up period in relation to PSA levels were as follows: 0 to 0.49 ng/mL, 0% (0/958); 0.50 to 0.99 ng/mL, 0.9% (17/1992); 1.00 to 1.49 ng/mL, 4.7% (54/1138); 1.50 to 1.99 ng/mL, 12.3% (70/571); 2.00 to 2.49 ng/mL, 21.4% (67/313); 2.50 to 2.99 ng/mL, 25.2% (56/222); 3.00 to 3.99 ng/mL, 33.3% (89/267); 4.00 to 6.99 ng/mL, 38.9% (103/265); 7.00 to 9.99 ng/mL, 50.0% (30/60); and for men with an initial PSA of 10.00 ng/mL or higher, 76.8% (53/69). Not a single case of prostate cancer was detected within 3 years in 2950 men (50.4% of the screened population) with an initial PSA level less than 1 ng/mL. CONCLUSIONS: Retesting intervals should be individualized on the basis of the PSA level, and the large group of men with PSA levels of less than 1 ng/mL can safely be scheduled for a 3-year testing interval. |
| first_indexed | 2024-03-06T21:51:28Z |
| format | Journal article |
| id | oxford-uuid:4b6b60ff-35fb-44b5-99ea-9eee0a0890be |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-06T21:51:28Z |
| publishDate | 2005 |
| record_format | dspace |
| spelling | oxford-uuid:4b6b60ff-35fb-44b5-99ea-9eee0a0890be2022-03-26T15:43:29ZIndividualized screening interval for prostate cancer based on prostate-specific antigen level: results of a prospective, randomized, population-based study.Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:4b6b60ff-35fb-44b5-99ea-9eee0a0890beEnglishSymplectic Elements at Oxford2005Aus, GDamber, JKhatami, ALilja, HStranne, JHugosson, JBACKGROUND: The aim of the present study was to evaluate the future cumulative risk of prostate cancer in relation to levels of prostate-specific antigen (PSA) in blood and to determine whether this information could be used to individualize the PSA testing interval. METHODS: The study included 5855 of 9972 men (aged 50-66 years) who accepted an invitation to participate in a prospective, randomized study of early detection for prostate cancer. We used a protocol based on biennial PSA measurements starting from 1995 and 1996. Men with serum PSA levels of 3.0 ng/mL or more were offered prostate biopsies. RESULTS: Among the 5855 men, 539 cases of prostate cancer (9.2%) were detected after a median follow-up of 7.6 years (up to July 1, 2003). Cancer detection rates during the follow-up period in relation to PSA levels were as follows: 0 to 0.49 ng/mL, 0% (0/958); 0.50 to 0.99 ng/mL, 0.9% (17/1992); 1.00 to 1.49 ng/mL, 4.7% (54/1138); 1.50 to 1.99 ng/mL, 12.3% (70/571); 2.00 to 2.49 ng/mL, 21.4% (67/313); 2.50 to 2.99 ng/mL, 25.2% (56/222); 3.00 to 3.99 ng/mL, 33.3% (89/267); 4.00 to 6.99 ng/mL, 38.9% (103/265); 7.00 to 9.99 ng/mL, 50.0% (30/60); and for men with an initial PSA of 10.00 ng/mL or higher, 76.8% (53/69). Not a single case of prostate cancer was detected within 3 years in 2950 men (50.4% of the screened population) with an initial PSA level less than 1 ng/mL. CONCLUSIONS: Retesting intervals should be individualized on the basis of the PSA level, and the large group of men with PSA levels of less than 1 ng/mL can safely be scheduled for a 3-year testing interval. |
| spellingShingle | Aus, G Damber, J Khatami, A Lilja, H Stranne, J Hugosson, J Individualized screening interval for prostate cancer based on prostate-specific antigen level: results of a prospective, randomized, population-based study. |
| title | Individualized screening interval for prostate cancer based on prostate-specific antigen level: results of a prospective, randomized, population-based study. |
| title_full | Individualized screening interval for prostate cancer based on prostate-specific antigen level: results of a prospective, randomized, population-based study. |
| title_fullStr | Individualized screening interval for prostate cancer based on prostate-specific antigen level: results of a prospective, randomized, population-based study. |
| title_full_unstemmed | Individualized screening interval for prostate cancer based on prostate-specific antigen level: results of a prospective, randomized, population-based study. |
| title_short | Individualized screening interval for prostate cancer based on prostate-specific antigen level: results of a prospective, randomized, population-based study. |
| title_sort | individualized screening interval for prostate cancer based on prostate specific antigen level results of a prospective randomized population based study |
| work_keys_str_mv | AT ausg individualizedscreeningintervalforprostatecancerbasedonprostatespecificantigenlevelresultsofaprospectiverandomizedpopulationbasedstudy AT damberj individualizedscreeningintervalforprostatecancerbasedonprostatespecificantigenlevelresultsofaprospectiverandomizedpopulationbasedstudy AT khatamia individualizedscreeningintervalforprostatecancerbasedonprostatespecificantigenlevelresultsofaprospectiverandomizedpopulationbasedstudy AT liljah individualizedscreeningintervalforprostatecancerbasedonprostatespecificantigenlevelresultsofaprospectiverandomizedpopulationbasedstudy AT strannej individualizedscreeningintervalforprostatecancerbasedonprostatespecificantigenlevelresultsofaprospectiverandomizedpopulationbasedstudy AT hugossonj individualizedscreeningintervalforprostatecancerbasedonprostatespecificantigenlevelresultsofaprospectiverandomizedpopulationbasedstudy |